[Insufficient elevation of TSH before therapy with I131 in a patient with metastatic differentiated thyroid carcinoma]
| Autor: | Ramírez Stieben LA; Unidad de Tiroides y Paratiroides del Grupo Gamma. ramirez.stieben@gmail.com., Queralt M; Servicio de Oncología del Grupo Gamma. marianaq9@hotmail.com., Sylvestre Begnis G; Servicio de Cirugía General del Grupo Gamma. gsylvestrebegnis@grupogamma.com., Polillo D; Servicio de Diagnóstico por imágenes del Grupo Gamma . dpolillo@grupogamma.com., Barrenechea I; Servicio de Neurocirugía del Grupo Gamma. ibarrenechea@grupogamma.com. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) [Rev Fac Cien Med Univ Nac Cordoba] 2023 Jun 30; Vol. 80 (2), pp. 149-152. Date of Electronic Publication: 2023 Jun 30. |
| DOI: | 10.31053/1853.0605.v80.n2.38112 |
| Abstrakt: | Guidelines suggest a thyrotropin (TSH) stimulation level ≥30 mIU/l for the administration of 131-iodine (I131) in patients with differentiated thyroid carcinoma (DTC). We present a patient with follicular thyroid carcinoma (FTC), with spinal metastasis as the initial manifestation, who after 6 weeks without levothyroxine did not present an elevation of ≥30 mIU/l of TSH. This situation was interpreted as secondary to the presence of functioning metastases and it was decided, regardless of the TSH level, to administer a therapeutic dose of I131, with iodine-uptake lesions in the liver and spine being confirmed. (Universidad Nacional de Córdoba) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|